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Abstract
Mutations in succinate dehydrogenase (SDH) lead to the development of tumors in 
a restricted subset of cell types, including chromaffin cells and paraganglia. The 
molecular basis for this specificity is currently unknown. We show that loss of SDH 
activity in a chromaffin cell model does not perturb complex I function, retaining 
the ability to oxidize NADH within the electron transport chain. This activity sup-
ports continued oxidation of substrates within the tricarboxylic acid (TCA) cycle. 
However, due to the block in the TCA cycle at SDH, the high glutamine oxidation ac-
tivity is only maintained through an efflux of succinate. We also show that although 
the mitochondria of SDH-deficient cells are less active per se, their higher mass per 
cell results in an overall respiratory rate that is comparable with wild-type cells. 
Finally, we observed that when their mitochondria are uncoupled, SDH-deficient 
cells are unable to preserve their viability, suggesting that the mitochondrial meta-
bolic network is unable to compensate when exposed to additional stress. We there-
fore show that in contrast to models of SDH deficiency based on epithelial cells, a 
chromaffin cell model retains aspects of metabolic “health,” which could form the 
basis of cell specificity of this rare tumor type.
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1 |  INTRODUCTION
Succinate dehydrogenase (SDH), also known as complex 
II (CII) of the electron transport chain (ETC), has a unique 
function within the mitochondrial metabolic network, being 
part of both the ETC and the tricarboxylic acid (TCA) cycle. 
As such, SDH activity was thought to be universally required 
for cell proliferation and survival. However, loss of any one of 
the four subunits of this enzyme leads to the development of 
rare tumor types including pheochromocytoma and paragan-
glioma (PPGL), gastrointestinal stromal tumors (GIST), and 
cases of renal cancer.1 The function of SDH within the mito-
chondrial matrix is to oxidize succinate to fumarate with the 
resulting electrons reducing the ubiquinone pool of the ETC. 
SDH deficiency therefore results in a well-characterized in-
crease in succinate levels in the matrix, which on reaching 
the cytosol inhibits members of the 2-oxoglutarate-dependent 
dioxygenase family of enzymes, eliciting epigenetic changes 
and pseudohypoxic signaling that are likely the major drivers 
of tumorigenesis.2,3
However, despite being originally described in 2000,4 
little is still known concerning how loss of SDH function 
can be tolerated, and why only in a highly restricted num-
ber of cell types. Although loss of function mutations in 
SDHB-D subunits is almost entirely restricted to oncogen-
esis, the first description of a loss of function mutation in 
SDHA was described in neurodegenerative disease, caus-
ing Leigh syndrome.1,5,6 Importantly, the mutations ob-
served in Leigh syndrome are distinct from those reported 
in tumors, suggesting that mutations in different members 
of the complex, and indeed different regions of SDHA may 
have distinct effects on the overall biochemistry of SDH. 
Indeed, using a model of SDH loss based on deletion of 
Sdhb in a kidney epithelial cell line, it was recently shown 
that tumor-specific mutations of SDH can compromise ac-
tivity of complex I,7,8 while those observed in Leigh syn-
drome do not.8 However, data from SDH-deficient PPGL 
and a chromaffin cell-based model with reduced (knocked-
down) Sdhb expression reported around the same time 
suggested that it may not be the case in this model.9 The 
existence of models of SDH deficiency using different 
cell types therefore provides an opportunity to resolve the 
question regarding the tissue specificity of tumorigenesis 
arising from loss of this metabolic enzyme.
It is clear from recent studies in multiple cell models of 
SDH deficiency that aspects of the TCA cycle retain func-
tion.7,8,10 There is therefore considerable plasticity within 
the mitochondrial metabolic network, although it is likely 
that this comes at a cost to the cell—a well-described con-
sequence being the increased production of reactive oxygen 
species (ROS). These molecules are produced as a result of 
the dependence of mitochondrial metabolism on redox ac-
tive reactions. Mitochondrial respiration is based on molec-
ular oxygen accepting electrons that arise from two reduced 
pyridine nucleotides; NADH and FADH2, which are them-
selves most  often  generated through dehydrogenase reac-
tions within the TCA cycle. Loss or reduction of the ability 
to oxidize these pyridines, as observed in conditions such as 
hypoxia as well as loss of SDH function, restricts the capa-
bility of the TCA cycle to generate the necessary substrates 
for macromolecule synthesis, such as aspartate.7,10-12
It therefore remains unclear what the cellular or microen-
vironmental conditions are that permit the continued viabil-
ity and proliferation required for tumorigenesis despite loss 
of SDH function. We report here that in contrast to epithe-
lial cell models of SDH loss, chromaffin cells lacking SDH 
retain complex I function, and are capable of oxidizing di-
verse substrates that may contribute to the metabolic fitness 
of the cells. However, this comes at a cost to the cell, as they 
demonstrate little spare respiratory capacity and are highly 
sensitive to mitochondrial uncoupling. We therefore suggest 
that at least part of the reason for the restriction of SDH mu-
tation-driven tumors to specific cell types may be due to the 
retention of complex I activity, reducing the need to remodel 
the metabolic network associated with the NADH:NAD+ 
redox pair, allowing continued viability and proliferation.
2 |  MATERIALS AND METHODS
2.1 | Cell culture and chemicals
Previously characterized immortalized mouse chromaffin 
cell lines deficient in Sdhb (Sdhb−/− CL6 and CL8) as well 
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as their Sdhb+/+ counterparts were maintained in Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) and 1 mM pyruvate. The same cell 
culture conditions were used for the mouse adrenal fibro-
blasts (MAF), Sdhb+/+ and Sdhb−/−. All chemicals, includ-
ing DMEM and FBS, were from Sigma-Aldrich unless stated 
otherwise. Brightfield images were taken using an EVOS FL 
(Thermo Scientific), at 10× magnification.
2.2 | High-resolution respirometry
For the measurement in intact state, trypsinized cells were 
resuspended in cell culture media (4.5 g/L glucose + 1 mM 
pyruvate) and loaded in an Oxygraph-2k (Oroboros instru-
ments) chamber. After closing the chambers and record-
ing routine respiration, oligomycin (2.5  μM) was added 
to inhibit ATP synthase. Measurements of the non-phos-
phorylating electron transfer system (ETS) capacity were 
obtained through stepwise (0.5  μM) titration of the un-
coupler, carbonyl cyanide 4-(trifluoromethoxy)phenylhy-
drazone (FCCP). Respiration was inhibited by addition of 
rotenone (0.5  μM) and antimycin A (2.5  μM) at the end 
of the experiment. For the measurement in permeabilized 
state, trypsinized and washed cells were resuspended in 
respiratory media Mir05 (110  mM sucrose, 60  mM  K+-
lactobionate, 0.5 mM EGTA, 3 mM MgCl2, 20 mM taurine, 
10 mM KH2PO4, 20 mM HEPES, 1 g/L BSA [essentially 
fatty acid free], pH 7.1). After closing the chambers and 
recording respiration on endogenous substrates, digitonin 
was added to permeabilize the cells. Substrate combina-
tions were used as indicated in the graphs. The concen-
trations used were 2 mM malate (Mal), 10 mM glutamate 
(Glu), 5 mM pyruvate (Pyr), and 10 mM succinate (suc). 
For fatty acid oxidation (FAO) assessment, limiting malate 
was used at concentration 0.05 mM and either 40 μM pal-
mitoylcarnitine or 200 μM octanoylcarnitine. In all experi-
ments on permeabilized cells, 3  mM ADP was used and 
maximum respiratory capacity was reached by stepwise 
titration of FCCP. Respiration was inhibited by addition 
of 0.5 μM rotenone and antimycin A (2.5 μM) in the end 
of the experiment. Values after antimycin A addition were 
subtracted from all recorded values. For the experiments 
with 13C tracers, FCCP and inhibitors were omitted. For 
mitochondrial measurements, the permeabilization step 
was omitted.
2.3 | Mitochondrial membrane potential 
measurement
Trypsinized cells were resuspended in Mir05 medium at 
0.5 mg/mL protein concentration on ice, and supplemented 
with 20 nM Tetramethylrhodamine ethyl ester dye (TMRE; 
Santa Cruz) and respiratory substrates as indicated at con-
centrations as for the respirometry measurements, before 
being permeabilized with 0.1 μg digitonin per μg protein for 
5 minutes at room temperature and immediately measured on 
Fortessa LSR-II flow cytometer (Beckton Dickinson). Each 
set of samples was assessed in three states: untreated (just 
TMRE and respiratory substrates), state 3 (+3  mM ADP), 
and uncoupled (100 μM FCCP). The relative mitochondrial 
membrane potential was determined from the difference of 
the coupled phosphorylating condition with ADP and the de-
polarized value.
2.4 | Mitochondrial mass evaluation
Cells in culture were incubated for 20 minutes with 100 nM 
MitoTracker Green (Thermo Fisher Scientific), before trypsi-
nization, washing (PBS), and resuspension in PBS supple-
mented with MitoTracker Green (100  nM). Where shown, 
cells were pre-incubated with FCCP (100  µM) to depolar-
ize the mitochondria 5 minutes before being incubated with 
MitoTracker Green. The fluorescence signal was assessed 
using Fortessa LSR-II flow cytometer (Beckton Dickinson), 
and mitochondrial mass expressed relative to fluorescence 
signal in Sdhb+/+ cells.
For citrate synthase activity, 1 × 106 trypsinized cells were 
washed with PBS and frozen before lysis in 200 μL of 50 mM 
Tris (pH 8) with 4 × freeze-thaw cycles in liquid nitrogen/
water bath. The assay was performed on 5 μL of cleared su-
pernatant added to 90 μL of reaction buffer (0.1 mM DTNB, 
0.3 mM Acetyl CoA, 0.1% Triton X-100 in 100 mM Tris-
HCl, pH 8) in 96-well plate. The baseline absorbance was 
measured in Fluostar Omega plate reader (BMG Labtech) at 
412 nm for 15 minutes, then 5 μL of 10 mM oxaloacetate was 
added and the absorbance measured for further 15 minutes. 
Baseline signal was subtracted from the signal measured after 
oxaloacetate addition.
2.5 | ATP assessment
Measurement of cellular ATP was performed using a 
bioluminescent assay (Sigma; FLAA) as per manufac-
turer's instructions. 24  hours before measurement, cells 
were seeded at 2 × 103 per well in a 96-well plate. Where 
shown, oligomycin (2.5 µM) was added 10 minutes prior 
to lysis. After removal of media, cells were washed in 
PBS (pH 7.4) and lysed in 50  μL of buffer. 100  μL of 
ATP assay was added to all wells before luminescence 
was read (BMG PHERAstar). Data were normalized to 
total protein per well using a BCA assay (ThermoFisher 
Scientific).
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2.6 | Total cell protein and cell 
size evaluation
1 × 106 trypsinized cells were washed with PBS and lysed in 
60 μL of RIPA buffer for 30 minutes. Protein concentration 
in the cleared supernatant was determined using the BCA 
protein method (Thermo Fisher Scientific). For cell size 
evaluation, cells were measured in the CASY TT cell counter 
and their diameter was recorded.
2.7 | Immunoblotting
Cells were lysed in modified RIPA buffer before dilution and 
quantitation using a bicinchoninic acid (BCA) assay. Lysates 
were diluted in Laemmli buffer before using 25 µg for elec-
trophoretic separation using SDS-PAGE. After blotting onto 
nitrocellulose membrane, the following antibodies were used 
to identify expression of cellular proteins: ACTB, OGDH 
(Proteintech; #15212-1-AP), PDH E1α (Proteintech; 18068-
1-AP), PDHK1 (Cell Signaling; #3820), PDK4 (Proteintech; 
12949-1-AP), and PGC1α (Cell Signaling #3820). Images 
were digitally acquired using a ChemiDoc XRS+ System 
(Bio Rad).
2.8 | Cell growth assay
Cell growth was assayed using the Sulforhodamine-B (SRB) 
assay. Cells were plated day before the treatment and after 
3 days growth in the presence of the drug cells were fixed 
in the plates by addition of 20% ice cold trichloracetic acid 
(TCA) for at least 30 minutes. Fixed cells were then washed 
with water, left to dry and stained with 0.4% SRB dye dis-
solved in 1% acetic acid. Superfluous dye was washed off 
with 1% acetic acid and when dry, dissolved in 50 mM Tris-
HCl pH 8 and the absorbance measured on Fluostar Omega 
plate reader (BMG Labtech) at 510 nm.
2.9 | Mitochondria isolation
Mitochondria were isolated using modified methodology 
described by Frezza et al.13 Briefly, trypsinized and washed 
cells were homogenized for 5  minutes in isolation buffer 
(200 mM sucrose, 10 mM Tris-MOPS, 1 mM EGTA-Tris; 
pH 7) using glass/Teflon homogenizer at speed 1000  rpm. 
Homogenate was then centrifuged at 600 g for 10 minutes, 
pellet discarded, and supernatant centrifuged at 3000 g for 
5  minutes. Mitochondria in the supernatant were then pel-
leted at 10 000 g for 15 minutes. Pelleted mitochondria were 
resuspended in ~50 μL of isolation buffer and let stand on 
ice for at least 1 hour before their respiration was assessed. 
During this time, protein concentration was determined by 
BCA protein method (Thermo Fisher Scientific).
2.10 | 13C labeling
Cells were prepared as described for the respirometry meas-
urements and after plasma membrane permeabilization with 
digitonin, 3 mM ADP and 13C labeled (all CK isotopes) and 
unlabeled respiratory substrates were added as indicated 
(1 mM malate, 10 mM glutamate, 5 mM pyruvate, and 3 mM 
glutamine) and left to respire in opened Oxygraph-2k cham-
bers for 40 minutes. Then the chambers were closed again, 
respiration signal recorded and cytochrome c was added to 
check for mitochondrial integrity. Contents of the chambers 
were collected in precooled Eppendorf tubes, centrifuged at 
10 000 g for 5 minutes, washed once with ice-cold saline, and 
frozen immediately on dry ice. For cell-based 13C labeling, 
13C16-palmitic acid (50  μM) or 13C5 glutamine (2  mM; all 
CK Isotopes) were added to cells for 3 days in “flux media”; 
DMEM powder (Sigma) supplied with sodium bicarbo-
nate as per manufacturer's instructions, 10% FBS and unla-
beled forms of glucose and/or glutamine depending on the 
13C-enriched nutrient employed. After the incubation period, 
cells were washed with saline and scraped off the precooled 
plates into methanol/H2O mixture. For spent media analysis, 
200 μL of cleared media was extracted. In all cases, 0.5 μg/
sample of D-6 glutaric acid (CDN Isotopes) supplied in H2O 
was used as internal standard and polar metabolites were 
extracted using Methanol:H2O:Chloroform at ratio 1:1:1. 
Briefly, samples were vortexed vigorously, left to shake with 
all the solvents for 15 minutes at 4°C and then centrifuged 
for 15 minutes at 16 000 g. The upper polar phase was col-
lected and evaporated in the Savant vacuum system (Thermo 
Fisher Scientific) and used for Gas Chromatography—Mass 
Spectrometry (GC-MS) analysis.
2.11 | GC-MS analysis
The dried extract was first incubated at 95°C in open tubes and 
then solubilized in 40 μL of 2% methoxyamine HCl in pyridine 
followed by 60 minutes incubation at 60°C and subsequently 
60  μL N-tertbutyldimethylsilyl-N-methyltrifluoroacetamide 
with 1% (w/v) tertbutyldimethyl-chlorosilane derivatization 
reagent was added. The suspension was incubated for an hour 
at 60°C in a well-sealed tube to prevent evaporation. Finally, 
the samples were centrifuged at 16 000 g for 5 minutes and 
the clear supernatant was transferred to a chromatography vial 
with a glass insert (Thermo Fisher Scientific) and processed 
immediately to GC-MS analysis. For analysis of the derivat-
ized samples, an Agilent 7890B Series GC/MSD gas chro-
matograph with a polydimethylsiloxane GC column coupled, 
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with a mass spectrometer (GC-MS) (Agilent Technologies 
UK Limited, Stockport, UK) was used. Prior to sample anal-
ysis, the GC-MS was tuned to a full width at half maximum 
(FWHM) peak width of 0.60 a.m.u. in the mass range of 50-
650 mass to charge ratio (m/z) using PFTBA tuning solu-
tion. 1 μL of sample was injected into the GC-MS in splitless 
mode with helium carrier gas at a rate of 1.0 mL min−1. The 
inlet liner containing glass wool was set to a temperature of 
270°C. Oven temperature was set at 100°C for 1 minute be-
fore ramping to 280°C at a rate of 5°C min−1. Temperature 
was further ramped to 320°C at a rate of 10°C min−1 held at 
320°C for 5 minutes. Compound detection was carried out 
in full scan mode in the mass range 50-650  m/z, with 2-4 
scans  sec−1, a source temperature of 250°C, a transfer line 
temperature of 280°C and a solvent delay time of 6.5 min-
utes. The injector needle was cleaned with acetonitrile three 
times before measurement commencement and three times 
following every measurement thereafter. The raw GC-MS 
data were converted to common data format using the ac-
quisition software and further processing of the isotope data 
including isotope correction and mass isotopomer analysis/
batch quantification was performed on metabolite detector 
software. The raw peak area for each analyte of interest was 
calculated using the metabolite detector software followed by 
normalizing the response to the internal standard peak area.
2.12 | Gene expression data
Gene expression profiles of human tumors were available from 
a previous study, in which 186 fully genotyped PPGL were 
analyzed.14,15 The data are shown for a subset of these sam-
ples carrying germline and somatic mutations in RET (n = 19), 
NF1 (n = 37), VHL (n = 40) or SDHx (n = 23) genes, as well 
as two samples of normal adrenal medulla. HG-U133 Plus 2.0 
Affymetrix GeneChip data from this previous study are avail-
able online as ArrayExpress entry E-MTAB-733 (http://www.
ebi.ac.uk/array expre ss/). Gene expression profiles of wild-type 
and Sdhb−/− MAF and imCC (CL6 and CL8) were assessed in 
duplicates using the GeneChip® Mouse Gene 1.0 ST Array.10 
Data are available as ArrayExpress entry E-MTAB-3403. 
Principal component analysis (PCA) and hierarchical cluster-
ing were performed using ClustVis software16 with default set-
tings using a gene list of 35 PGC1a target genes and metabolic 
enzymes. Heatmap shows data filtered for genes showing a 
>1.5-fold difference between WT and KO imCC.
2.13 | Statistical analysis
One-way or two-way ANOVA was used to assess sta-
tistical significance; *P  ≤  .05, **P  ≤  .01, ***P  ≤  .001, 
****P ≤ .0001.
3 |  RESULTS
Tumor-associated mutations in SDH, all of which result in 
loss of oxidative enzymatic activity, lead to tumor formation 
in a restricted set of cell types—most often chromaffin cells 
and paraganglia. Previous studies performed in epithelial cell 
types suggested that mutations in SDH subunits that under-
pin tumor formation lead to loss of complex I activity and 
a restricted metabolic phenotype.8,17 We therefore sought to 
confirm whether this metabolic phenotype was also observed 
in a physiologically relevant model derived from chromaf-
fin cells compared to a genetically identical model derived 
from a non-tumor-forming cell type, adrenal fibroblasts 
(MAFs).10 We first assessed oxygen consumption of intact 
cells and found that although loss of SDH activity in the 
MAF model decreased oxygen consumption consistent with 
that previously reported (Figure 1A), SDH-deficient chro-
maffin cells (imCC) retained a similar respiratory phenotype 
to their wild-type counterparts (Figure 1B). Interestingly, in 
both cell models, loss of SDH resulted in no change in ATP 
synthesis-independent respiration (Figure 1A,B). However, 
maximal capacity of the electron transport chain (FCCP-
uncoupled respiration) was greatly reduced in both SDH-
mutated cell models (Figure 1A,B), suggesting that use of 
electrons in ATP synthesis was reduced independently of cell 
type. We therefore assessed cellular ATP content between 
wild-type and SDH-deficient cells, and found that indeed it 
was significantly lower in both SDH-deficient cell models. 
To test reliance of the cells on the mitochondrial ATP syn-
thase, we incubated them with the inhibitor, oligomycin, and 
observed that the wild-type cells were able to compensate 
with increased glycolytic ATP production, resulting in no net 
change in cellular ATP (Figure 1C). Interestingly, although 
the SDH-deficient MAFs also showed a similar ATP con-
tent after oligomycin, the SDH-deficient imCC cells dem-
onstrated a significant increase in ATP (Figure 1C). These 
data demonstrate that the ATP synthase is instead working in 
reverse in this cell model, hydrolyzing ATP to contribute to 
the maintenance of the transmembrane proton gradient, much 
like previously observed in ischemia.18,19
To assess mitochondrial respiratory phenotype inde-
pendently of the cytosol, permeabilized cells were incubated 
with saturating concentrations of respiratory substrates for 
complex I, and subsequently complex II. ADP-stimulated 
(state 3) complex I-supported respiration was found to be 
lower in the SDH-deficient MAF model compared to wild-
type controls, again in contrast to the chromaffin cell model 
(Figure 1D,E). However, in both models, the expected loss 
of succinate-driven (complex II) activity was observed in 
SDH-deficient cells. These data suggest that the loss of 
complex I activity observed in intact SDH-deficient cells 
may be through an alteration in the generation or avail-
ability of NADH for complex I activity, rather than an 
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F I G U R E  1  A and B, Respiration of intact MAF (A) or imCC (B) cells. Leak was determined through the use of oligomycin (2.5 µM), while 
maximal condition was defined through addition of FCCP in 0.5 μM steps until maximal rate was observed. Results shown are from 4 (MAF) or 
3 (imCC) independent experiments, presented as mean ± SD. Two-way ANOVA was used to assess statistical significance; **P < .01, P < .001, 
****P < .0001. C, ATP content in both imCC and MAF cell lines, in the presence or absence of oligomycin (2.5 µM, pre-incubated for 10 minutes 
before lysis), presented as a mean of at least four independent experiments, each in technical triplicate ± SEM. Ns; not significant, ****P < .0001. 
D and E, Respiration (oxygen consumption) of permeabilized MAF (D) and imCC (E) cells in basal (Mir05) medium. Additions as follows: Glu/
Mal; glutamate (10 mM) and malate (2 mM), ADP (3 mM), Succ; succinate (10 mM) or maximal; FCCP titrated in 0.5 μM steps. Results shown are 
from four independent experiments, presented as mean ± SD. ns; not significant, *P < .05, **P < .01, ****P < .0001. F, UCP2 mRNA expression 
showing that both Sdhb-deficient clones have >80% reduction in UCP2 expression. G, Effect of the proton ionophore FCCP on cell growth over 
3 days in culture. Results are from three independent experiments performed in triplicate, presented as mean ± SEM
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inherent defect of mitochondria. Consistent with the data 
from intact cells, loss of maximal respiratory phenotype 
(FCCP-stimulated) was observed in permeabilized cells 
(on complex I and II substrates; Figure 1D,E). These data, 
alongside those suggesting a reversal of the ATP synthase 
(Figure 1C) suggested that SDH-deficient cells may be sen-
sitive to uncoupling of the respiratory chain. Indeed, ex-
pression of the uncoupling protein, UCP2 was significantly 
reduced in the SDH-deficient cell models, consistent with 
this hypothesis (Figure 1F and Supplementary Figure 1A). 
Importantly, when UCP2 levels were compared between 
SDH-mutated and non-SDH-mutated patient tumor 
samples, only the former exhibited reduced expression 
(Supplementary Figure 1B), confirming that this was a 
phenotype only relevant to SDH-deficient tumors. We 
therefore incubated both wild-type and SDH-deficient cells 
with increasing concentrations of FCCP before assessing 
cell number after 3  days. We observed a significant sen-
sitization of the SDH-deficient cells, with an LD50 around 
50% lower than that of wild-type cells (Figure 1G).
Despite the clear similarities between the MAF and 
imCC cell models, a significant difference was observed in 
complex I activity between models, with imCC cells retain-
ing activity and the MAF cell model demonstrating a signif-
icant reduction in function, as previously described (Figure 
1A,B,D,E).8,17 This suggested that this cell type was able to 
retain a more wild-type like TCA cycle activity in the ab-
sence of SDH compared to the MAFs, which could confer 
at least part of the tissue specificity of SDH mutant tumors. 
The respiratory phenotype of the imCCs was therefore in-
vestigated in more detail. Previous studies have suggested 
that the cytosolic redox balance is altered in SDH-deficient 
cells, and that the addition of exogenous pyruvate can sup-
port metabolic function.7 In addition to supporting cytoso-
lic redox, pyruvate has also been shown as a carbon source 
in the mitochondria of SDH-deficient cells,7,10 supporting 
proliferation (Supplementary Figure 2A). We therefore in-
vestigated complex I-linked respiration in permeabilized 
SDH-deficient cells in the presence of exogenous pyruvate 
and found that although respiration was unchanged, max-
imal respiratory capacity was increased (Figure 2A). This 
suggested that pyruvate oxidation within the mitochondria 
may be limiting in SDH-deficient cells, perhaps due to a 
significant demand for oxaloacetate through carboxylation 
to produce aspartate.7,10 These data suggested that SDH-
deficient imCC cells are not deficient in complex I function, 
due to the fact that the oxidative decarboxylation of pyru-
vate is used to reduce NAD+ to NADH. We therefore tested 
this using an alternative NADH-producing substrate—fatty 
acids (FA). During the course of mitochondrial β-oxida-
tion, FA are stepwise degraded to acetyl CoA units. Each of 
these steps produces FADH2 and NADH, which contribute 
electrons to the respiratory chain via the electron transport 
flavoprotein (ETF) and complex I. Using either octanoyl- or 
palmitoyl-carnitine, we found that both FA are efficient re-
spiratory substrates for SDH-deficient cells (Figure 2B,C). 
Indeed, respiration on palmitoyl-carnitine exceeded that of 
the wild-type cells. These measurements provide further 
confirmation of complex I functionality in SDH-deficient 
cells and suggest that FA could be an energetic fuel in the 
absence of full SDH function. This is supported by the fact 
that SDH-deficient cells showed increased susceptibility to 
the FA oxidation inhibitor etomoxir (Supplementary Figure 
2B), although they showed little difference in the incor-
poration of palmitate-derived 13C-labeled acetyl CoA units 
into TCA cycle (Supplementary Figure 2C).
Due to the apparent differences in respiratory capacity 
and sensitivity to uncoupling, we investigated whether per-
meabilized SDH-deficient cells maintained a high mito-
chondrial membrane potential in the presence of saturating 
concentrations of respiratory substrates. This appeared to be 
the case (Figure 2D), but when normalized to increased mi-
tochondrial content using MitoTracker Green (Figure 2E), 
no difference was observed (Figure 2F). Importantly, we 
confirmed that MitoTracker Green staining was unaffected 
by mitochondrial membrane potential (Supplementary 
Figure 2D). As mitochondrial content can also be assessed 
using citrate synthase activity, this was also examined as an 
independent measurement, but found not to vary between 
wild-type and SDH-deficient cells (Figure 2G). These 
results suggested that SDH-deficient cells may upregu-
late their mitochondrial mass to compensate for reduced 
metabolic efficiency arising through mechanisms such 
as ROS-mediated damage of matrix proteins, or reduced 
matrix protein content—the latter resulting in a less dense 
matrix. Respiratory experiments performed on isolated 
mitochondria support this observation, as these show de-
creased respiration on glutamate/malate combination and 
similar respiration in the presence of glutamate/malate/py-
ruvate when expressed per mitochondrial protein (Figure 
2H). Importantly, SDH-deficient cells are larger than their 
wild-type counterparts (Figure 2I and Supplementary 
Figure 2E,F)—consistent with them containing enlarged 
mitochondria (Figure 2E). We therefore investigated 
whether SDH-deficient cells increase PGC1a expression as 
a marker of increased mitochondrial biogenesis, but found 
instead decreased expression (Supplementary Figure 2G). 
These data suggest that the change in mitochondrial mass is 
unlikely to be due to increased biogenesis, but more likely 
due to matrix swelling as a result of metabolic dysfunction.
To investigate the metabolic pathways that SDH-
deficient cells use to support complex I-linked respiration 
in more depth, we investigated the metabolism of 13C4-
malate supplied to permeabilized cells as before (G+M; 
Figure 3A), but incubated for 45  minutes—a time point 
previously shown to approach steady state.20 Although 
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limited incorporation of 13C from malate was observed in 
succinate (Figure 3B), which is most likely due to the pres-
ence of unlabeled glutamate, we observed similar labeling 
of m + 4 citrate between wild-type and SDH-deficient cells, 
indicative of citrate synthase activity. This was confirmed 
by similar levels of the m + 6 citrate isotopomer, which is 
the product of the condensation of 13C4-oxaloacetate (OAA) 
and 13C2-acetyl CoA (Figure 3C). Labeling of acetyl CoA 
occurs through oxidation of labeled pyruvate, which itself 
is derived either from OAA or malate through the action of 
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mitochondrial phosphoenolpyruvate carboxykinase (PCK2) 
or malic enzyme (ME2) activities, respectively (Figure 
3A). High levels of pyruvate-forming activity in these con-
ditions were confirmed through the presence of the m + 3 
isotopomer of alanine (Figure 3D).21 We and others have 
previously shown upregulation of pyruvate carboxylase 
in SDH-deficient cells and tumors, which would support 
anaplerotic pyruvate use in the mitochondria.7,10 In light of 
the results above, we investigated the expression of enzymes 
involved in central carbon metabolism in the mitochondria, 
and observed a number with significant differential changes 
in mRNA expression between MAF and imCC model 
(Supplementary Figure 3A). Given that PDHA1 and PDK4, 
two enzymes involved in the regulation of pyruvate oxida-
tion, demonstrated altered expression, we assessed them at 
the protein level and found that they were both significantly 
downregulated, but in both cell models (Supplementary 
Figure 3B). These data suggest that changes in pyruvate ox-
idation that may occur downstream of these alterations in 
protein expression are unlikely to explain cell type-specific 
metabolic alterations observed.
To investigate TCA cycle pathways downstream of ci-
trate, we omitted glutamate from the system and used either 
a combination of 13C4-malate and unlabeled pyruvate (Figure 
3E), or 13C5-glutamine/unlabeled malate (Figure 3I). When 
13C4-malate was supplied together with unlabeled pyruvate, 
clear evidence of citrate synthase activity in both cell lines 
was observed (m  +  4 isotopomer), which constituted 90% 
of the total citrate pool in SDH-deficient cells and 70% in 
wild-type (Figure 3F). Continued oxidation of citrate to yield 
succinate appeared to be higher in SDH-deficient cells com-
pared to wild-type cells (m + 2 succinate isotopomer; Figure 
3G) confirming the absence of any metabolic defect in the 
TCA cycle between citrate synthase and SDH, and there-
fore efficient NADH-oxidizing activity in the SDH-deficient 
chromaffin cells. The mass isotopomer distribution is inde-
pendent of pool size so this difference is expected to be inde-
pendent of the truncation of the TCA cycle in SDH-deficient 
cells and concomitant succinate accumulation. In both cell 
lines, 90% of all fumarate was synthesized through fumarate 
hydratase activity, suggestive of relatively low SDH activity 
even in wild-type chromaffin cells (Figure 3H). When the 
permeabilized cells were incubated with unlabeled malate in 
combination with 13C5 glutamine, around 80% of all citrate 
was unlabeled in SDH-deficient cells while this was ~60% 
in wild-type cells, the predominant isotopomers arose from 
TCA cycle oxidation activity (m + 2 and m + 4 isotopomers; 
Figure 3J). Interestingly, although glutamine-derived gluta-
mate was similar in both conditions (Figure 3K), downstream 
production of succinate was increased in SDH-deficient cells, 
as expected (Figure 3L). These results suggest that the re-
spiratory substrates provided to mitochondria in selectively 
permeabilized cells are metabolized in a similar manner in-
dependent of SDH function. We have previously shown that 
expression of many of the enzymes involved in the reductive 
carboxylation of glutamine is altered independently of cell 
model at the mRNA level.10 Due to the increased glutamate 
oxidation observed, we investigated the expression of 2-ox-
oglutarate (α-ketoglutarate) dehydrogenase (OGDH), part of 
the OGDH complex, and a critical control point for gluta-
mate oxidation within TCA cycle. We found that it was not 
substantially altered in either cell model (Supplementary 
Figure 3C).
It was recently shown that after pharmacological in-
hibition of SDH, complex I-dependent respiration was 
preserved due to glutamine oxidation accompanied by 
succinate efflux out of mitochondria and the cell.8 It was 
further suggested that this mechanism sustains respiration 
in cells with neurodegeneration-associated SDHA mutation 
and suggested that the ability to use this normally redun-
dant metabolic shunt may explain the different phenotype 
in SDH-mutations-associated tumors versus neurodegener-
ative disorders.8 In our study, we report that respiration was 
found to be similar between wild-type and SDH-deficient 
chromaffin cells (Figure 1B) due to a maintenance of 
complex I activity. We therefore investigated whether 
succinate efflux  specifically supported glutamine oxida-
tion in our model. We incubated SDH-deficient cells with 
13C5-glutamine, and indeed observed a high rate of glu-
tamine-derived succinate efflux, with close to 75% of all 
F I G U R E  2  A, Respiration (oxygen consumption) of permeabilized imCCs in basal state (Mir05 medium), or with the following 
additions: Glu/Mal/Pyr/ADP; glutamate (10 mM), malate (2 mM) and pyruvate (5 mM), ADP (3 mM), followed by FCCP to stimulate maximal 
respiration. *P < .05, **P < .01 (two-way ANOVA, Dunnett's post-test). B and C, Respiration of fatty acids—palmitate (B) and octanoate 
(C). Palmitoylcarnitine (40 μM) or octanoylcarnitine (200 μM) were added with limiting concentrations of malate (0.05 mM), with ADP 
(3 mM), followed by FCCP (maximal) to stimulate maximal respiration as above. **P < .01, ***P < .001, ****P < .001 (two-way ANOVA, 
Dunnett's post-test). D, Mitochondrial membrane potential (Δψ) assessed in the presence of indicated substrates. The substrates were: 10 mM 
glutamate (Glu), 2 mM malate (Mal), 5 mM pyruvate (Pyr), 10 mM succinate (Succ), or 200 μM octanoylcarnitine and 0.05 M malate (Mal/
Oct). ***P < .001, ****P < .001 (two-way ANOVA, Dunnett's post-test). E, Mitochondrial mass assessed with 100 nM of Δψ insensitive dye 
MitoTracker Green. P < .05 (t test with Welch's correction). F, Δψ normalized to mitochondrial mass ([data shown in D]/[data shown in E]). G, 
Citrate synthase activity assessed per cell number. H, Respiration of isolated mitochondria in the presence of 3 mM ADP and different substrate 
combinations as indicated. The substrates were 10 mM glutamate (Glu), 2 mM malate (Mal), 5 mM pyruvate (Pyr), and 10 mM succinate (Succ). 
**P < .01, ****P < .0001 (two-way ANOVA, Dunnett's post-test). I, Cell size presented as peak diameter (PDI) of the cells in suspension. 
****P < .0001. Results shown are from 3 to 4 independent experiments and presented as mean ± SD, apart from G and I, which were 4 and 3 
independent samples, respectively
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cellular succinate arising from glutamine (compared to 32% 
in wild-type cells; Figure 4A), which was also observed in 
the medium (Figure 4B,C). This suggests that glutamine 
oxidation is highly active in the chromaffin model of Sdhb 
loss, and could explain the sustained respiration observed. 
Consistent with their increased glutamine requirement, in-
hibition of glutaminolysis with BPTES, a potent inhibitor 
of glutaminase, reduced growth or increased cell death of 
SDH-deficient cells more efficiently than in their wild-type 
counterparts (Figure 4D).
4 |  DISCUSSION
SDH-mutated tumors arise from one of very few cell types, 
which include chromaffin cells, paraganglia, and gastroin-
testinal stromal cells.22 Given that these cell types have not 
been shown to have a higher inherent rate of mutation than 
others, it suggests that they are able to tolerate loss of this 
central metabolic enzyme while other cell types cannot. 
Indeed, this is a common theme in tumors driven by mu-
tations in metabolic enzymes: loss of fumarate hydratase 
F I G U R E  3  Metabolism of 13C labeled respiratory substrates. A, Scheme of TCA cycle with SDH enzyme (yellow box) and accompanying 
redox reaction producing NADH (highlighted in blue) during the labeling experiment with 13C4 malate and non-labeled glutamate in the Oxygraph-
2k. Black full circles represent 13C carbon atoms. B-D, Relative contribution of succinate (B), citrate (C), and alanine (D) isotopomers to total 
cellular pool in the Oxygraph-2k labeling experiment with 1 mM 13C4 malate and unlabeled 10 mM glutamate. E, Scheme of TCA cycle with SDH 
enzyme (yellow box) and accompanying redox reaction producing NADH (highlighted in blue) during the labeling experiment with 13C4 malate 
and non-labeled pyruvate in the Oxygraph-2k. Black full circles represent 13C carbon atoms. F-H, Relative contribution of citrate (F), succinate 
(G), and fumarate (H) isotopomers to total cellular pool in the Oxygraph-2k labeling experiment with 1 mM 13C4 malate and non-labeled 5 mM 
pyruvate. I, Scheme of TCA cycle with SDH enzyme (yellow box) and accompanying redox reaction producing NADH (highlighted in blue) during 
the labeling experiment with13C5 glutamine and non-labeled malate in the Oxygraph-2k. Black full circles represent 13C carbon atoms. J-L, Relative 
contribution of citrate (J), glutamate (K), and succinate (L) isotopomers to total cellular pool in the Oxygraph-2k labeling experiment with 3 mM 
13C5 glutamine with non-labeled 1 mM malate. Data shown are a product of 2-3 independent experiments performed in duplicate and individual 
results pooled for final evaluation presented as mean ± SD
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is observed to arise most frequently in myocytes of the 
smooth muscle and renal epithelium while oncogenic mu-
tations in isocitrate dehydrogenase 1 are most often ob-
served in tumors arising from glial cells, myeloid cells, and 
chondrocytes.22
This study represents the first to investigate comprehen-
sively mitochondrial metabolic function after loss of Sdhb, 
in chromaffin cells. It is important to note that many of the 
metabolic phenotypes observed in the chromaffin model de-
scribed here and published previously mirror those described 
in other Sdhb−/− models based on non-physiologically rele-
vant cell types; adrenal fibroblast (described here), renal,7,8 
and breast epithelia.17 In these models, both respiration of 
intact cells and complex I-specific activity were found to 
be lower in SDH-deficient cells compared with wild-type 
(Figure 1).7,8,17 We show here that this is not the case in a 
chromaffin cell-derived model, which retains complex I 
function and a respiratory activity comparable to wild-type 
cells. Furthermore, it appears that they maintain the supply 
of acetyl co-A through a combination of pyruvate and fatty 
acid oxidation. However, our data also suggest that when FA 
oxidation is inhibited, SDH-deficient chromaffin cells are 
unable to compensate with additional contribution from py-
ruvate, which is most likely due to inhibition of pyruvate de-
hydrogenase by HIF-dependent upregulation of the inhibitory 
kinase, pyruvate dehydrogenase kinase 1 (Supplementary 
Figure 3B).23 Finally, we also provide evidence to suggest 
that in the imCC cell model, the mitochondrial ATP synthase 
functions as an ATP-hydrolyzing proton pump, in contrast to 
the MAF cell model. This is consistent with the increased 
sensitivity of these SDH-deficient cells to the ionophore, 
FCCP (Figure 1G), which dissipates the proton gradient 
and therefore likely increases the rate of mitochondrial ATP 
hydrolysis to a rate that is unsustainable for the cells.
It is important to note that some of the respiratory phe-
notype observed in the chromaffin model is likely due to 
the increased mitochondrial mass observed that was not 
apparent in the breast epithelial model.17 Increased mi-
tochondrial mass downstream of SDH deficiency is con-
sistent with previous observations made in SDH-mutated 
F I G U R E  4  Glutamine oxidation and succinate efflux in Sdhb−/− cells. A, Relative contribution to intracellular succinate pool from 13C5 
glutamine. B, Relative contribution to effluxed succinate pool from 13C5 glutamine. C, Relative contribution of succinate isotopomers to total 
extracellular succinate pool from 13C5 glutamine. D, Cell growth over period of 3 days in the presence of 2 or 10 μM BPTES. In (A-C), experiments 
were done in tetraplicate and results shown are presented as mean ± SD. In (D) 4, independent experiments were done in triplicate and results are 
shown as mean ± SEM. One-way ANOVA was used to assess statistical significance; ****P ≤ .0001
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PPGL, which are characterized by the presence of signifi-
cant number of defective mitochondria.24,25 Indeed, a sim-
ilar mitochondrial morphology and increase in mass was 
observed in other SDHB-mutated tumor types as well as 
in Sdhb+/− mice.26,27 However, this increase may come at a 
cost to the cell; the mitochondria themselves are less effi-
cient, and even small increases in electron flow were found 
to result in a reduction in viability (Figure 1G). Importantly, 
the clear differences between the chromaffin and non-chro-
maffin cell models observed in this study are also reflected 
in previous studies using these models, where glucose and 
glutamine oxidation, which generate NADH, were retained 
in the Sdhb−/− chromaffin cell model, which was less appar-
ent in the epithelial cell models.7,10
It is therefore clear from the cell model data both previously 
published and presented here that, in parallel with the etiology 
of SDHB-deficient tumors, the tissue of origin of the SDH-
deficient cell may be critical to their ability to cope with loss 
of SDH activity. We suggest that at least some of this is likely 
due to the retention of complex I function, which maintains a 
more favorable NAD+:NADH, reducing the need for additional 
metabolic re-wiring. The respiration of SDH-deficient cells is 
supported by increased but incomplete glutamine oxidation. 
However, this is not sufficient to ensure reserve respiratory ca-
pacity and these cells show high sensitivity toward inhibition of 
glutaminolysis and mitochondrial uncoupling, features which 
could be taken advantage of for future therapeutic potential.
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